Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Individualized Anti-Cancer Vaccine (AlloVaxTM) Study in Patients With Refractory Hepatocellular Carcinoma (HCC)

NCT01995227 is registered in ClinicalTrials.gov with Mirror Biologics, Inc. as lead sponsor.

NCT NCT01995227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01995227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Individualized Anti-Cancer Vaccine (AlloVaxTM) Study in Patients With Refractory Hepatocellular Carcinoma (HCC)
Lead sponsor
Mirror Biologics, Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
December 31, 2013
Completion date
July 31, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma